Profound invariant natural killer T-cell deficiency in inflammatory arthritis

Annals of the Rheumatic Diseases

Volumn 69, Issue 10, 2010, Pages 1873-1879

  Tudhope, Susan J ^a   Von Delwig, Alexei ^a   Falconer, Jane ^a   Pratt, Arthur ^a   Woolridge, Tom ^b   Wilson, Gillian ^b   Isaacs, John D ^a   Ng, Wan Fai ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; C REACTIVE PROTEIN; ALPHA-GALACTOSYLCERAMIDE; ANTIRHEUMATIC AGENT; GALACTOSYLCERAMIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; CELL CULTURE; CELL PROLIFERATION; DIFFERENTIAL DIAGNOSIS; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NATURAL KILLER T CELL; OSTEOARTHRITIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRALGIA; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; CELL PROLIFERATION; CELLS, CULTURED; DIAGNOSIS, DIFFERENTIAL; FEMALE; GALACTOSYLCERAMIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; MALE; METHOTREXATE; MIDDLE AGED; NATURAL KILLER T-CELLS; OSTEOARTHRITIS; YOUNG ADULT;

EID: 77957263337     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.125849     Document Type: Article

References (36)

1. Wilson SB, Delovitch TL. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol 2003;3:211-22.
2. Cerundolo V, Silk JD, Masri SH, et al. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009;9:28-38.
3. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007;25:297-336.
4. Taniguchi M, Harada M, Kojo S, et al. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003;21:483-513. (Pubitemid 37174539)
5. Hammond KJ, Kronenberg M. Natural killer T cells: natural or unnatural regulators of autoimmunity? Curr Opin Immunol 2003;15:683-9. (Pubitemid 37434076)
6. Bendelac A, Lantz O, Quimby ME, et al. CD1 recognition by mouse NK1+ T lymphocytes. Science 1995;268:863-5.
7. Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997;278:1626-9.
8. Brossay L, Chioda M, Burdin N, et al. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 1998;188:1521-8.
9. Chiba A, Oki S, Miyamoto K, et al. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha-galactosylceramide. Arthritis Rheum 2004;50:305-13. (Pubitemid 38084316)
10. Kaieda S, Tomi C, Oki S, et al. Activation of invariant natural killer T cells by synthetic glycolipid ligands suppresses autoantibody-induced arthritis. Arthritis Rheum 2007;56:1836-45.
11. Coppieters K, Van Beneden K, Jacques P, et al. A single early activation of invariant NK T cells confers long-term protection against collagen-induced arthritis in a ligand-specific manner. J Immunol 2007;179:2300-9.
12. Lee PT, Benlagha K, Teyton L, et al. Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med 2002;195:637-41.
13. Montoya CJ, Pollard D, Martinson J, et al. Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology 2007;122:1-14.
14. Kojo S, Adachi Y, Keino H, et al. Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum 2001;44:1127-38. (Pubitemid 32433619)
15. Linsen L, Thewissen M, Baeten K, et al. Peripheral blood but not synovial fluid natural killer T cells are biased towards a Th1-like phenotype in rheumatoid arthritis. Arthritis Res Ther 2005;7:R493-502.
16. van der Vliet HJ, von Blomberg BM, Nishi N, et al. Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 2001;100:144-8.
17. Coppieters K, Dewint P, Van Beneden K, et al. NKT cells: manipulable managers of joint inflammation. Rheumatology (Oxford) 2007;46:565-71.
18. Kim HY, Kim HJ, Min HS, et al. NKT cells promote antibody-induced joint inflammation by suppressing transforming growth factor beta1 production. J Exp Med 2005;201:41-7.
19. Sandberg JK, Bhardwaj N, Nixon DF. Dominant effector memory characteristics, capacity for dynamic adaptive expansion, and sex bias in the innate Valpha24 NKT cell compartment. Eur J Immunol 2003;33:588-96.
20. Lucas M, Gadola S, Meier U, et al. Frequency and phenotype of circulating Valpha24/ Vbeta11 double-positive natural killer T cells during hepatitis C virus infection. J Virol 2003;77:2251-7.
21. Kukreja A, Cost G, Marker J, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002;109:131-40.
22. Gadola SD, Dulphy N, Salio M, et al. Valpha24-JalphaQ-independent, CD1d-restricted recognition of alpha-galactosylceramide by human CD4(+) and CD8alphabeta(+) T lymphocytes. J Immunol 2002;168:5514-20. (Pubitemid 34556130)
23. Lee PT, Putnam A, Benlagha K, et al. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 2002;110:793-800.
24. Araki M, Kondo T, Gumperz JE, et al. Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission. Int Immunol 2003;15:279-88.
25. Park SH, Weiss A, Benlagha K, et al. The mouse CD1d-restricted repertoire is dominated by a few autoreactive T cell receptor families. J Exp Med 2001;193:893-904.
26. Godfrey DI, MacDonald HR, Kronenberg M, et al. NKT cells: what's in a name? Nat Rev Immunol 2004;4:231-7.
27. Terabe M, Swann J, Ambrosino E, et al. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 2005;202:1627-33.
28. Peralbo E, DelaRosa O, Gayoso I, et al. Decreased frequency and proliferative response of invariant Valpha24Vbeta11 natural killer T (iNKT) cells in healthy elderly. Biogerontology 2006;7:483-92.
29. Jing Y, Gravenstein S, Chaganty NR, et al. Aging is associated with a rapid decline in frequency, alterations in subset composition, and enhanced Th2 response in CD1d-restricted NKT cells from human peripheral blood. Exp Gerontol 2007;42:719-32.
30. Molling JW, Kölgen W, van der Vliet HJ, et al. Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer 2005;116:87-93.
31. Benjamin M, McGonagle D. Histopathologic changes at "synovio- entheseal complexes" suggesting a novel mechanism for synovitis in osteoarthritis and spondylarthritis. Arthritis Rheum 2007;56:3601-9. (Pubitemid 350100693)
32. Haywood L, McWilliams DF, Pearson CI, et al. Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum 2003;48:2173-7.
33. Brooks P. Inflammation as an important feature of osteoarthritis. Bull WHO 2003;81:689-90.
34. Parietti V, Chifflot H, Sibilia J, et al. Rituximab treatment overcomes reduction of regulatory iNKT cells in patients with rheumatoid arthritis. Clin Immunol 2010;134:331-9.
35. Gumperz JE, Miyake S, Yamamura T, et al. Functionally distinct subsets of CD1-drestricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002;195:625-36. (Pubitemid 34461507)
36. Michel ML, Keller AC, Paget C, et al. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med 2007;204:995-1001.